Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

• Published in: Euro surveillance : bulletin européen sur les maladies transmissibles Vol. 25; no. 18; p. 1
• Main Authors: Jääskeläinen, Anne J, Kekäläinen, Eliisa, Kallio-Kokko, Hannimari, Mannonen, Laura, Kortela, Elisa, Vapalahti, Olli, Kurkela, Satu, Lappalainen, Maija
• Format: Journal Article
• Language: English
• Published: Sweden Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) 07.05.2020; European Centre for Disease Prevention and Control (ECDC)
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies; Automation, Laboratory; Betacoronavirus; Child; Child, Preschool; Clinical Laboratory Techniques - methods; Clinical Laboratory Techniques - standards; Coronavirus Infections - diagnosis; Coronavirus Infections - epidemiology; COVID-19; COVID-19 diagnostic tests; COVID-19 Testing; Enzyme-Linked Immunosorbent Assay - methods; Finland - epidemiology; Humans; Immunoassay; Immunoglobulin A - blood; Immunoglobulin G - blood; Medical screening; Middle Aged; Pandemics; Pneumonia, Viral - diagnosis; Pneumonia, Viral - epidemiology; Rapid Communication; Reagent Kits, Diagnostic - standards; Reproducibility of Results; Retrospective Studies; SARS-CoV-2; Sensitivity and Specificity; Severe acute respiratory syndrome coronavirus 2; Viral infections; Young Adult; Finland; COVID-19; IgG; IgA; SARS-CoV-2; commercial; serology
• ISSN: 1560-7917; 1025-496X; 1560-7917
• DOI: 10.2807/1560-7917.ES.2020.25.18.2000603

Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset.